Switching to injectable HIV treatment: patient experiences
This study looks at how people living with HIV feel about switching to a new injectable treatment called cabotegravir and rilpivirine. It aims to understand real-life experiences and quality of life after making the switch.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are living with HIV.
- You are switching to the injectable treatment cabotegravir and rilpivirine as part of your regular care.
- Your HIV viral load has been under 50 copies/mL for at least 6 months before starting the study.
- You are 18 years or older.
- You can read, understand, and answer questionnaires in French.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether switching from daily HIV pills to a long-acting injectable combination (cabotegravir and rilpivirine) is safe and effective for people whose HIV is well controlled. Instead of taking pills every day, you would receive a shot every month or two, which may be more convenient.
This study looks at how the long-acting injectable treatment for HIV affects your quality of life and how well it keeps the virus under control. If you've already completed the injections, you'll be asked to complete questionnaires about your experiences.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study looks at how long an injectable HIV treatment (cabotegravir and rilpivirine) keeps working in people whose virus is already well controlled. It aims to see the real-world experience and how long patients stay on this treatment.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study looks at people in Belgium who have already received at least one dose of a long-acting injectable HIV medication called cabotegravir/rilpivirine. The goal is to learn more about how this treatment works in real-world settings.
Hear when a new Quality of Life trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.